Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

Zydus Lifesciences Limited engages in the research, development, production, marketing, distribution, and sale of pharmaceutical products in India, the United States, and internationally. It operates through two segments: Pharmaceuticals and Consumer Products. It offers finished dosage human formulations, such as generics; branded generics; specialty formulations, including biosimilars and vaccines; active pharmaceutical ingredients; consumer wellness products; animal healthcare products; and products in the therapeutic areas of pain management, neurology, metabolic disorder, and liver diseases. The company provides the products under the Everyuth, Nutralite, SugarFree, Complan, Glucon-D, and Nycil brands. In addition, the company offers a pipeline of biological products in the areas of oncology, autoimmune disease, nephrology, inflammation, rheumatology, hepatology, and infectious illnesses. Further, it engages in the investment, animal health and veterinary, pharmacy retail, and manpower supply and administration activities. The company was formerly known as Cadila Healthcare Limited and changed its name to Zydus Lifesciences Limited in February 2022. Zydus Lifesciences Limited was founded in 1952 and is headquartered in Ahmedabad, India. Zydus Lifesciences Limited is a subsidiary of Zydus Family Trust.

Revenue projections:

Revenue projections for ZYDUSLIFE
Revenue projections for ZYDUSLIFE

With ZYDUSLIFE's revenue forecasted to drop below last year's level, investors are expected to take a cautious stance. Such declines typically affect a company's bottom line, reducing profitability and making investors hesitant to invest heavily in the company until financial performance improves.

Financial Ratios:

currentRatio 0.000000
forwardPE 22.178766
debtToEquity 34.305000
earningsGrowth 0.019000
revenueGrowth 0.303000
grossMargins 0.723500
operatingMargins 0.188270
trailingEps 49.060000
forwardEps 41.814770

Zydus Lifesciences Limited's Forward PE is positioned well, reflecting a favorable balance between stock price and earnings. The stock isn't overpriced, offering room for growth and making it a potentially rewarding investment as its value has room to rise further.
Zydus Lifesciences Limited's forward EPS falling below its trailing EPS suggests the company is expected to be less profitable this year. This signals a potential decline in earnings, which may raise concerns about Zydus Lifesciences Limited's financial future.

Price projections:

Price projections for ZYDUSLIFE
Price projections for ZYDUSLIFE

Zydus Lifesciences Limited's price projections have gradually decreased, reflecting a less optimistic view of the company's future performance. Analysts are adjusting their expectations, suggesting potential concerns about Zydus Lifesciences Limited's ability to meet previous growth targets.

Insider Transactions:

Insider Transactions for ZYDUSLIFE
Insider Transactions for ZYDUSLIFE


ZYDUSLIFE had 1 buy transactions, with market price at 951.4000244140625 per share.The period under consideration saw no buy transactions.The increased selling activity around Zydus Lifesciences Limited's current price levels may indicate further downside risk. If this trend continues, the stock's price could face additional declines as selling pressure intensifies.

Recommendation changes over time:

Recommendations trend for ZYDUSLIFE
Recommendations trend for ZYDUSLIFE


ZYDUSLIFE has received a favorable buy bias from analysts recently, positioning it as a solid investment opportunity. This sentiment may attract more investors, who view ZYDUSLIFE as a stable option to park their money and potentially benefit from the company's continued growth and profitability.